8 unchanged sentences
Performance Graph
−Removed: The stock performance graph below illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2018 to the Nasdaq Composite and a composite of ten Nasdaq Pharmaceutical and Specialty Pharmaceutical Stocks which most closely compare to our Company - Avadel Pharmaceuticals plc, Harrow Health, Inc., Eagle Pharmaceuticals, Inc., Assertio Holdings, Inc., HLS Therapeutics Inc., EyePoint Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Theratechnologies Inc., Acorda Therapeutics Inc.
+Added: The stock performance graph below illustrates a comparison of the total cumulative stockholder return on our common stock since December 31, 2019 to the Nasdaq Composite and a composite of ten Nasdaq Pharmaceutical and Specialty Pharmaceutical Stocks which most closely compare to our Company - Avadel Pharmaceuticals plc, Harrow Health, Inc., Eagle Pharmaceuticals, Inc., Assertio Holdings, Inc., HLS Therapeutics Inc., EyePoint Pharmaceuticals, Inc., Eton Pharmaceuticals, Inc., Theratechnologies Inc.
and Talphera, Inc.
3 unchanged sentences
In January 2019, the Company’s Board of Directors established the current $10.0 million repurchase program to replace the prior authorizations.
−Removed: We repurchased 402,143 shares and 367,793 shares of common stock for approximately $0.7 and $1.0 million during the years ended December 31, 2023 and 2022, respectively.
+Added: We repurchased 339,200 and 402,143 shares of common stock for approximately $0.6 million and $0.7 million during the years ended December 31, 2024 and 2023, respectively.
The following table summarizes the activity, by month, during the fourth quarter of 2024:
14 unchanged sentences
December 16,800 $2.17 16,800 $2,433,312
−Removed: (1) Of this amount, 25,000 shares were repurchased directly in private purchases at the then-current fair market value of common stock.
−Removed: (2) Of this amount, 971 shares were repurchased directly in private purchases at the then-current fair market value of common stock.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.